Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

On October 28, 2022, the Board of Directors of Instadose Pharma Corp was notified by our independent Auditor BF Borgers CPA PC (the "Auditor") that Instadose is required to disclose that the February 28, 2022, financial statements were not reviewed by the Auditor.

On November 2, 2022, the Company's Board of Directors met and then acting under authority delegated to it, approved the disclosure described below in this Form 8-K.

Instadose is advising that the financial statements as at February 28, 2022 and the associated 10-Q were not reviewed by the Auditor. Management of Instadose provided disclosure that the financial statements and 10-Q were unaudited, however, further disclosure is now being provided that the February 28, 2022, financial statements and 10-Q were also not reviewed by the Auditor.

Instadose has requested that the Auditor furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of the letter from the Auditor Firm is attached hereto as Exhibit 16.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
  16.1          Letter from BF Borgers CPA PC
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              Document)





2

© Edgar Online, source Glimpses